

WORLD HEART CORP
Form SC 13D/A
December 22, 2008

OMB APPROVAL
OMB Number: 3235-0145
Expires: February 28, 2009
Estimated average burden
hours per response. . . 14.5

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

World Heart Corporation

(Name of Issuer)

Common Stock, no par value per share

(Title of Class of Securities)

980905202

(CUSIP Number)

ABIOMED, Inc.

Edgar Filing: WORLD HEART CORP - Form SC 13D/A

Attn: General Counsel

22 Cherry Hill Drive

Danvers, MA 01923

(978) 646-1400

With a copy to:

Peter M. Rosenblum, Esq.

Foley Hoag LLP

155 Seaport Blvd.

Boston, MA 02210

(617) 832-1151

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

December 16, 2008

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. "

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**Persons who respond to the collection of information contained in this form are not
required to respond unless the form displays a currently valid OMB control number.**

1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only).

ABIOMED, Inc.

2. Check the Appropriate Box if a Member of a Group (See Instructions)

(a) ..

(b) ..

3. SEC Use Only

4. Source of Funds (See Instructions)

OO

5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e) ..

6. Citizenship or Place of Organization

Delaware

7. Sole Voting Power

Number of

Shares

Beneficially 2,731,666

8. Shared Voting Power

Owned by

Each

9. Sole Dispositive Power

Reporting

Person 2,731,666

10. Shared Dispositive Power

With

11. Aggregate Amount Beneficially Owned by Each Reporting Person

2,731,666

12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) ..

13. Percent of Class Represented by Amount in Row (11)

20.6%

14. Type of Reporting Person (See Instructions)

CO

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

The following constitutes Amendment No. 3 to the Schedule 13D originally filed by ABIOMED, Inc., a corporation organized under the laws of the State of Delaware (the Reporting Person) on December 11, 2007 with respect to its acquisition of shares of common stock, no par value (the Common Shares) of World Heart Corp., a Canadian corporation (the Issuer). This Amendment amends the Schedule 13D (as previously amended) as specifically set forth herein. The purpose of this Amendment is to reflect the disposition by the Reporting Person of 135,000. The share amounts set forth in this Amendment reflect a 30-for-1 reverse stock split with respect to the Common Shares, which was completed on October 27, 2008.

Item 5. Interest in Securities of the Issuer

(a) In the aggregate, the Reporting Person beneficially owns 2,731,666 Common Shares. The Issuer's Form 10-Q for the quarter ended September 30, 2008 reported that 13,253,964 Common Shares were outstanding as of November 4, 2008. Based on this number, the Common Shares beneficially owned by the Reporting Person constitute approximately 20.6% of the outstanding Common Shares.

(b) The Reporting Person has sole voting and dispositive power with respect to the Common Shares reported in this Schedule 13D.

(c) N/A

(d) On December 16, 2008, the Reporting Person sold 135,000 Common Shares in a privately negotiated transaction at a price of \$2.35 per share.

(e) N/A

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATE: December 22, 2008

ABIOMED, INC.

By: /s/ Michael R. Minogue
Michael R. Minogue

President and Chief Executive Officer